Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782.
No abstract available

Publication types

  • Clinical Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Benzodiazepines* / therapeutic use
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Neoplasm Recurrence, Local* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Benzodiazepines
  • loncastuximab tesirine